Skip Nav Destination
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia
Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II
Trends in survival of young adult patients with acute lymphoblastic leukemia in Sweden and the United States
Issue Archive
Table of Contents
BLOOD COMMENTARIES
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Clinical Trials & Observations
Emanuele Zucca,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Stephanie Rondeau,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Anna Vanazzi,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Bjørn Østenstad,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Ulrich J. M. Mey,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Daniel Rauch,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Björn E. Wahlin,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Felicitas Hitz,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Micaela Hernberg,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Ann-Sofie Johansson,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Peter de Nully Brown,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Hans Hagberg,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Andrés J. M. Ferreri,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Andreas Lohri,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Urban Novak,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Thilo Zander,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Hanne Bersvendsen,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Mario Bargetzi,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Walter Mingrone,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Fatime Krasniqi,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Stefan Dirnhofer,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Stefanie Hayoz,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Hanne Hawle,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Simona Berardi Vilei,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Michele Ghielmini,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group,Eva Kimby,for the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group
LYMPHOID NEOPLASIA
Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma
Xiaosheng Wu,Mary Stenson,Jithma Abeykoon,Kevin Nowakowski,Lianwen Zhang,Joshua Lawson,Linda Wellik,Ying Li,Jordan Krull,Kerstin Wenzl,Anne J. Novak,Stephen M. Ansell,Gail A. Bishop,Daniel D. Billadeau,Kah Whye Peng,Francis Giles,Daniel M. Schmitt,Thomas E. Witzig
There is a Blood Commentary on this article in this issue.
MYELOID NEOPLASIA
NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia
Brief Report
Alina Rudorf,Tony Andreas Müller,Cathrin Klingeberg,Stefanie Kreutmair,Teresa Poggio,Sivahari Prasad Gorantla,Tamina Rückert,Annette Schmitt-Graeff,Anina Gengenbacher,Peter Paschka,Claudia Baldus,Robert Zeiser,George S. Vassiliou,Allan Bradley,Justus Duyster,Anna Lena Illert
Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II
Brief Report
Courtney L. Jones,Brett M. Stevens,Angelo D’Alessandro,Rachel Culp-Hill,Julie A. Reisz,Shanshan Pei,Annika Gustafson,Nabilah Khan,James DeGregori,Daniel A. Pollyea,Craig T. Jordan
There is a Blood Commentary on this article in this issue.
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2
Carmelo Carmona-Rivera,Sami S. Khaznadar,Kyawt W. Shwin,Jorge A. Irizarry-Caro,Liam J. O’Neil,Yudong Liu,Kenneth A. Jacobson,Amanda K. Ombrello,Deborah L. Stone,Wanxia L. Tsai,Daniel L. Kastner,Ivona Aksentijevich,Mariana J. Kaplan,Peter C. Grayson
There is a Blood Commentary on this article in this issue.
LETTER TO BLOOD
Trends in survival of young adult patients with acute lymphoblastic leukemia in Sweden and the United States
Clinical Trials & Observations
BLOOD WORK
-
Cover Image
Cover Image
Immunofluorescence photomicrograph of neutrophil extracellular traps (NETs, in red) triggered by exposure of neutrophils to 16 μM adenosine for 4 hours. Adenosine-mediated NET formation is implicated in a monogenic form of vasculitis known as deficiency of adenosine deaminase 2 (DADA2). See the article by Carmona-Rivera et al on page 395.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals